Compare Stocks → Exposed: 10 CENT Crypto to Explode May 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AEHANASDAQ:AMLXNASDAQ:DMACNASDAQ:SYRS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAAesther Healthcare Acquisition$9.96+4.2%$10.25$8.20▼$14.22$131.77M0.04434,237 shs1.29 million shsAMLXAmylyx Pharmaceuticals$1.71-1.2%$2.16$1.70▼$26.44$116.30M-0.682.55 million shs1.19 million shsDMACDiaMedica Therapeutics$2.85-1.0%$2.80$1.94▼$4.75$109.34M1.7539,388 shs12,558 shsSYRSSyros Pharmaceuticals$5.00+0.6%$5.30$2.09▼$8.17$132.84M1.75108,260 shs291,378 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAAesther Healthcare Acquisition0.00%0.00%0.00%0.00%0.00%AMLXAmylyx Pharmaceuticals-1.16%-5.00%-2.84%-91.26%-93.11%DMACDiaMedica Therapeutics-1.04%-6.25%+10.89%-5.94%+3.64%SYRSSyros Pharmaceuticals+0.60%-11.50%-0.79%-30.46%+35.14%Exposed: 10 CENT Crypto to Explode May 20th? (Ad)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAMLXAmylyx Pharmaceuticals4.0686 of 5 stars4.14.00.00.02.54.21.3DMACDiaMedica Therapeutics2.243 of 5 stars3.55.00.00.03.40.00.0SYRSSyros Pharmaceuticals4.1506 of 5 stars3.51.00.04.33.23.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAAesther Healthcare AcquisitionN/AN/AN/AN/AAMLXAmylyx Pharmaceuticals2.25Hold$28.671,576.41% UpsideDMACDiaMedica Therapeutics3.00Buy$7.00145.61% UpsideSYRSSyros Pharmaceuticals3.00Buy$14.00180.00% UpsideCurrent Analyst RatingsLatest AEHA, DMAC, AMLX, and SYRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2024SYRSSyros PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/14/2024AMLXAmylyx PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $3.005/10/2024AMLXAmylyx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.004/24/2024DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.004/8/2024AMLXAmylyx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.004/3/2024SYRSSyros PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$13.004/1/2024SYRSSyros PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.003/21/2024DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.003/21/2024DMACDiaMedica TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $6.003/18/2024AMLXAmylyx PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral3/11/2024AMLXAmylyx PharmaceuticalsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 5/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAAesther Healthcare AcquisitionN/AN/AN/AN/A($0.14) per shareN/AAMLXAmylyx Pharmaceuticals$380.79M0.31$0.59 per share2.89$6.42 per share0.27DMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.22 per shareN/ASYRSSyros Pharmaceuticals$6.98M19.14N/AN/A$0.56 per share8.93Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAAesther Healthcare Acquisition-$560KN/A0.00∞N/AN/AN/AN/AN/AAMLXAmylyx Pharmaceuticals$49.27M-$1.07N/AN/AN/A-17.86%4.14%3.49%8/8/2024 (Estimated)DMACDiaMedica Therapeutics-$19.38M-$0.56N/A∞N/AN/A-36.21%-34.45%8/12/2024 (Estimated)SYRSSyros Pharmaceuticals-$164.57M-$5.01N/AN/AN/A-1,656.34%-395.36%-88.41%8/13/2024 (Estimated)Latest AEHA, DMAC, AMLX, and SYRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2024Q1 2024SYRSSyros Pharmaceuticals-$0.89-$0.79+$0.10-$1.48$1.30 millionN/A 5/10/2024Q1 2024AMLXAmylyx Pharmaceuticals$0.24-$0.46-$0.70$0.83$113.26 million$88.64 million 5/8/2024Q1 2024DMACDiaMedica Therapeutics-$0.16-$0.14+$0.02-$0.14N/AN/A3/27/2024Q4 2023SYRSSyros Pharmaceuticals-$1.23-$1.19+$0.04-$0.20$2.40 million$0.39 million3/20/2024N/ADMACDiaMedica Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAAesther Healthcare AcquisitionN/AN/AN/AN/AN/AAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEHAAesther Healthcare AcquisitionN/A0.290.29AMLXAmylyx PharmaceuticalsN/A4.484.48DMACDiaMedica TherapeuticsN/A18.1418.14SYRSSyros Pharmaceuticals1.973.013.01OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAAesther Healthcare Acquisition78.64%AMLXAmylyx Pharmaceuticals95.84%DMACDiaMedica Therapeutics10.12%SYRSSyros Pharmaceuticals91.47%Insider OwnershipCompanyInsider OwnershipAEHAAesther Healthcare Acquisition19.80%AMLXAmylyx Pharmaceuticals11.70%DMACDiaMedica Therapeutics7.20%SYRSSyros Pharmaceuticals12.26%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAEHAAesther Healthcare Acquisition2,02113.23 million10.61 millionNot OptionableAMLXAmylyx Pharmaceuticals38468.01 million60.05 millionOptionableDMACDiaMedica Therapeutics1837.96 million35.23 millionOptionableSYRSSyros Pharmaceuticals6826.73 million23.45 millionOptionableAEHA, DMAC, AMLX, and SYRS HeadlinesRecent News About These CompaniesMay 21, 2024 | marketbeat.comAssenagon Asset Management S.A. Has $909,000 Holdings in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)May 17, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Syros Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:SYRS)May 16, 2024 | marketbeat.comFY2026 Earnings Forecast for Syros Pharmaceuticals, Inc. Issued By Brookline Capital Management (NASDAQ:SYRS)May 16, 2024 | markets.businessinsider.comOptimistic Outlook for Syros Pharmaceuticals with Promising Clinical Trials and Regulatory AdvancementsMay 15, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Issues Earnings Results, Beats Estimates By $0.10 EPSMay 15, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Syros Pharmaceuticals (NASDAQ:SYRS)May 15, 2024 | markets.businessinsider.comHere's what Wall Street expects from Syros Pharmaceuticals's earningsMay 15, 2024 | finance.yahoo.comSyros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...May 15, 2024 | finance.yahoo.comQ1 2024 Syros Pharmaceuticals Inc Earnings CallMay 14, 2024 | msn.comSyros Pharmaceuticals GAAP EPS of -$0.10 beats by $0.77May 14, 2024 | msn.comSYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024May 14, 2024 | businesswire.comSyros Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateMay 12, 2024 | marketbeat.comShort Interest in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Drops By 22.0%May 7, 2024 | businesswire.comSyros to Participate in Upcoming Investor ConferencesMay 7, 2024 | businesswire.comSyros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024May 2, 2024 | marketbeat.comSyros Pharmaceuticals (NASDAQ:SYRS) Stock Price Passes Below 50 Day Moving Average of $5.94May 1, 2024 | zacks.comAnalysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out forApril 10, 2024 | marketwatch.comSyros Pharmaceuticals Shares Rise 20% on FDA Fast-Track Designation for TamibaroteneApril 10, 2024 | zacks.comSyros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AMLApril 10, 2024 | zacks.comSyros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?April 9, 2024 | msn.comSyros jumps on FDA fast track tag for leukemia drugNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAesther Healthcare AcquisitionNASDAQ:AEHAAesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the pharmaceutical and medical devices sectors. The company was incorporated in 2021 and is based in New York, New York.Amylyx PharmaceuticalsNASDAQ:AMLXAmylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.DiaMedica TherapeuticsNASDAQ:DMACDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Syros PharmaceuticalsNASDAQ:SYRSSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.